Auteurs
Analysis
Allemagne
Racine
Analysis
Allemagne
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur les relations entre la France et l'Australie - Analysis (Allemagne)

Index « Auteurs » - entrée « Bijoyesh Mookerjee »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Bijoy K. Menon < Bijoyesh Mookerjee < Biju George  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 4.
Ident.Authors (with country if any)Title
000048 (2017) Dirk Schadendorf [Allemagne] ; Georgina V. Long [Australie] ; Daniil Stroiakovski [Russie] ; Boguslawa Karaszewska [Pologne] ; Axel Hauschild [Allemagne] ; Evgeny Levchenko [Russie] ; Vanna Chiarion-Sileni [Italie] ; Jacob Schachter [Israël] ; Claus Garbe [Allemagne] ; Caroline Dutriaux [France] ; Helen Gogas [Grèce] ; Mario Mandalà [Italie] ; John B A G. Haanen [Pays-Bas] ; Céleste Lebbé [France] ; Andrzej Mackiewicz [Pologne] ; Piotr Rutkowski [Pologne] ; Jean-Jacques Grob [France] ; Paul Nathan [Royaume-Uni] ; Antoni Ribas [États-Unis] ; Michael A. Davies [États-Unis] ; Ying Zhang [États-Unis] ; Mathilde Kaper [États-Unis] ; Bijoyesh Mookerjee [États-Unis] ; Jeffrey J. Legos [États-Unis] ; Keith T. Flaherty [États-Unis] ; Caroline Robert [France]Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.
000D65 (2015) Georgina V. Long [Australie] ; Daniil Stroyakovskiy [Russie] ; Helen Gogas [Grèce] ; Evgeny Levchenko [Russie] ; Filippo De Braud [Italie] ; James Larkin [Royaume-Uni] ; Claus Garbe [Allemagne] ; Thomas Jouary [France] ; Axel Hauschild [Allemagne] ; Jean-Jacques Grob [France] ; Vanna Chiarion-Sileni [Italie] ; Celeste Lebbe [France] ; Mario Mandalà [Italie] ; Michael Millward [Australie] ; Ana Arance [Espagne] ; Igor Bondarenko [Ukraine] ; John B A G. Haanen [Pays-Bas] ; Johan Hansson [Suède] ; Jochen Utikal [Allemagne] ; Virginia Ferraresi [Italie] ; Nadezhda Kovalenko [Russie] ; Peter Mohr [Allemagne] ; Volodymr Probachai [Ukraine] ; Dirk Schadendorf [Allemagne] ; Paul Nathan [Royaume-Uni] ; Caroline Robert [France] ; Antoni Ribas [États-Unis] ; Douglas J. Demarini [États-Unis] ; Jhangir G. Irani [États-Unis] ; Suzanne Swann [États-Unis] ; Jeffrey J. Legos [États-Unis] ; Fan Jin [États-Unis] ; Bijoyesh Mookerjee [États-Unis] ; Keith Flaherty [États-Unis]Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
000D76 (2015) Jean Jacques Grob [France] ; Mayur M. Amonkar [États-Unis] ; Boguslawa Karaszewska [Pologne] ; Jacob Schachter [Israël] ; Reinhard Dummer [Suisse] ; Andrzej Mackiewicz [Pologne] ; Daniil Stroyakovskiy [Russie] ; Kamil Drucis [Pologne] ; Florent Grange [France] ; Vanna Chiarion-Sileni [Italie] ; Piotr Rutkowski [Pologne] ; Mikhail Lichinitser [Russie] ; Evgeny Levchenko [Russie] ; Pascal Wolter [Belgique] ; Axel Hauschild [Allemagne] ; Georgina V. Long [Australie] ; Paul Nathan [Royaume-Uni] ; Antoni Ribas [États-Unis] ; Keith Flaherty [États-Unis] ; Peng Sun [États-Unis] ; Jeffrey J. Legos [États-Unis] ; Diane Opatt Mcdowell [États-Unis] ; Bijoyesh Mookerjee [États-Unis] ; Dirk Schadendorf [Allemagne] ; Caroline Robert [France]Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
001867 (2012) Hans-Joachim Schmoll [Allemagne] ; David Cunningham [Royaume-Uni] ; Alberto Sobrero [Italie] ; Christos S. Karapetis [Australie] ; Philippe Rougier [France] ; Sheryl L. Koski [Canada] ; Ilona Kocakova [République tchèque] ; Igor Bondarenko [Ukraine] ; György Bodoky [Hongrie, Espagne] ; Paul Mainwaring [Australie] ; Ramon Salazar [Espagne] ; Peter Barker [États-Unis] ; Bijoyesh Mookerjee [États-Unis] ; Jane Robertson [Royaume-Uni] ; Eric Van Cutsem [Belgique]Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

List of associated KwdEn.i

Nombre de
documents		Descripteur
3Humans
3Imidazoles (administration & dosage)
3Melanoma (drug therapy)
3Oximes (administration & dosage)
3Pyridones (administration & dosage)
3Pyrimidinones (administration & dosage)
2Adult
2Aged
2Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
2Disease-Free Survival
2Female
2Male
2Middle Aged
2Protein Kinase Inhibitors (therapeutic use)
2Proto-Oncogene Proteins B-raf (genetics)
2Risk Factors
2Treatment Outcome
1Administration, Oral
1Advanced stage
1Aged, 80 and over
1Antiangiogenic agent
1Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
1Antineoplastic Combined Chemotherapy Protocols (adverse effects)
1Antineoplastic agent
1Bevacizumab
1Biomarkers, Tumor (genetics)
1Cancerology
1Cediranib
1Colorectal cancer
1Comparative study
1DNA Mutational Analysis
1Disease Progression
1Double blind study
1Double-Blind Method
1Drug Administration Schedule
1Drug Therapy, Combination
1First line treatment
1Genetic Predisposition to Disease
1Human
1Imidazoles (adverse effects)
1Imidazoles (therapeutic use)
1Indoles (administration & dosage)
1Indoles (adverse effects)
1Indoles (therapeutic use)
1Intention to Treat Analysis
1L-Lactate Dehydrogenase (metabolism)
1MAP Kinase Kinase Kinases (antagonists & inhibitors)
1MAP Kinase Kinase Kinases (metabolism)
1Melanoma (genetics)
1Melanoma (metabolism)
1Melanoma (mortality)
1Melanoma (pathology)
1Melanoma (secondary)
1Mutation
1Neoplasm Metastasis (pathology)
1Oximes (adverse effects)
1Oximes (therapeutic use)
1Phase III trial
1Phenotype
1Predictive Value of Tests
1Prognosis
1Prospective Studies
1Protein Kinase Inhibitors (administration & dosage)
1Protein Kinase Inhibitors (adverse effects)
1Proto-Oncogene Proteins B-raf (antagonists & inhibitors)
1Pyridones (adverse effects)
1Pyridones (therapeutic use)
1Pyrimidinones (adverse effects)
1Pyrimidinones (therapeutic use)
1Quality of Life
1Randomization
1Skin Neoplasms (drug therapy)
1Skin Neoplasms (genetics)
1Skin Neoplasms (mortality)
1Skin Neoplasms (pathology)
1Sulfonamides (administration & dosage)
1Sulfonamides (adverse effects)
1Sulfonamides (therapeutic use)
1Surveys and Questionnaires
1Survival Analysis
1Time Factors
1Vascular endothelium growth factor
1Young Adult

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Bijoyesh Mookerjee" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i  \
                -Sk "Bijoyesh Mookerjee" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Allemagne
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Bijoyesh Mookerjee
}}
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024